| Brian A Bucina, DO | |
|
200 Lee St, Winslow, AZ 86047-2603 | |
| (928) 289-3396 | |
| (928) 289-2801 |
| Full Name | Brian A Bucina |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 18 Years |
| Location | 200 Lee St, Winslow, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902010549 | NPI | - | NPPES |
| 787516 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 5101016779 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Little Colorado Medical Center | Winslow, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Winslow Memorial Hospital Inc | 8628988409 | 34 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, announced today that it has received U.S. Food and Drug Administration approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2 (HIV-2).
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of a memorandum of understanding with the Kanagawa Prefecture of Japan.
A new study describes the cytopathic episodes triggered by SARS-CoV-2 with virus replication processes in frozen-hydrated cells.
› Verified 6 days ago
| Entity Name | Winslow Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477653889 PECOS PAC ID: 8628988409 Enrollment ID: O20040224001246 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, announced today that it has received U.S. Food and Drug Administration approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2 (HIV-2).
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of a memorandum of understanding with the Kanagawa Prefecture of Japan.
A new study describes the cytopathic episodes triggered by SARS-CoV-2 with virus replication processes in frozen-hydrated cells.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian A Bucina, DO 200 Lee St, Winslow, AZ 86047-2603 Ph: (928) 289-3396 | Brian A Bucina, DO 200 Lee St, Winslow, AZ 86047-2603 Ph: (928) 289-3396 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, announced today that it has received U.S. Food and Drug Administration approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2 (HIV-2).
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of a memorandum of understanding with the Kanagawa Prefecture of Japan.
A new study describes the cytopathic episodes triggered by SARS-CoV-2 with virus replication processes in frozen-hydrated cells.
› Verified 6 days ago
Dr. Rishi Tejas Dholakia, DO, MPH Surgery Medicare: Accepting Medicare Assignments Practice Location: 500 Indiana Ave, Winslow, AZ 86047 Phone: 928-289-4646 | |
Gregory Jarrin, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 500 Indiana Ave, Winslow, AZ 86047 Phone: 928-289-4646 Fax: 928-289-6290 | |
Dilip K Parikh, M.D Surgery Medicare: Medicare Enrolled Practice Location: 200 East Lee Street, Winslow, AZ 86047 Phone: 928-289-3396 Fax: 928-289-2801 |